Sentry Investment Management LLC Has $90,000 Stock Holdings in Biogen Inc. (NASDAQ:BIIB)

Sentry Investment Management LLC decreased its position in Biogen Inc. (NASDAQ:BIIB) by 14.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 589 shares of the biotechnology company’s stock after selling 96 shares during the period. Sentry Investment Management LLC’s holdings in Biogen were worth $90,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Allworth Financial LP grew its position in shares of Biogen by 12.9% during the 3rd quarter. Allworth Financial LP now owns 1,181 shares of the biotechnology company’s stock worth $229,000 after buying an additional 135 shares during the period. Diversify Advisory Services LLC bought a new position in Biogen in the third quarter valued at approximately $877,000. Farther Finance Advisors LLC grew its holdings in Biogen by 2.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 7,656 shares of the biotechnology company’s stock worth $1,484,000 after acquiring an additional 160 shares during the period. Robeco Institutional Asset Management B.V. raised its position in shares of Biogen by 27.8% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 274,708 shares of the biotechnology company’s stock valued at $53,249,000 after acquiring an additional 59,771 shares during the last quarter. Finally, Old North State Wealth Management LLC lifted its stake in shares of Biogen by 0.7% in the 3rd quarter. Old North State Wealth Management LLC now owns 13,533 shares of the biotechnology company’s stock valued at $2,623,000 after purchasing an additional 100 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Stock Performance

Shares of BIIB stock opened at $139.88 on Friday. Biogen Inc. has a 12 month low of $128.51 and a 12 month high of $238.00. The company’s fifty day simple moving average is $144.55 and its 200-day simple moving average is $169.15. The firm has a market cap of $20.47 billion, a PE ratio of 12.50, a P/E/G ratio of 1.51 and a beta of -0.08. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 EPS for the quarter, topping the consensus estimate of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%. Equities research analysts expect that Biogen Inc. will post 15.83 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BIIB shares. Mizuho decreased their price objective on Biogen from $251.00 to $207.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Royal Bank of Canada decreased their target price on Biogen from $231.00 to $225.00 and set an “outperform” rating for the company in a research report on Thursday, February 13th. StockNews.com downgraded shares of Biogen from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 28th. TD Cowen decreased their price objective on shares of Biogen from $300.00 to $275.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Finally, Wells Fargo & Company cut their target price on shares of Biogen from $165.00 to $140.00 and set an “equal weight” rating on the stock in a report on Thursday, February 13th. Seventeen research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, Biogen currently has a consensus rating of “Hold” and a consensus target price of $213.33.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.